The open-label, multiple-dose, dose-escalation study is enrolling about 15 patients with relapsed or refractory multiple myeloma, DLBCL and MCL, who will receive SNS01-T, a drug designed to selectively trigger apoptosis in B-cell cancers, via intravenous infusion
Isis Pharmaceuticals Inc., of Carlsbad, Calif., said preliminary data from a dose-escalation Phase I trial showed that treatment with ISIS-STAT3RX resulted in clear responses in patients with advanced cancer who were refractory to prior chemotherapy treatment, with an acceptable safety profile
Initiation of the study followed a successful, dose-escalation Phase I study in which clinical activity was observed in five of seven patients receiving the two highest dose levels
A follow-up, multidose, dose-escalation trial is planned for the beginning of 2013...Vaximm AG, of Basel, Switzerland, said it completed enrollment in a Phase I/II dose-escalation study testing oral therapeutic cancer vaccine VXM01
Cleveland BioLabs Inc., of Buffalo, N.Y., and Incuron LLC, a joint venture between the firm and Bioprocess Capital Ventures, said the first patient was dosed in a Phase I single-agent, dose-escalation trial testing the oral formulation of CBL0137 in subjects with advanced solid tumors who are resistant or refractory to standard of care...Up to 36 patients will be enrolled in the dose-escalation arm, with an additional nine to 12 patient enrolled in the dose confirmation arm
The company plans to start a single-agent, dose-escalation and expansion study in hematologic cancers in 2012...The open-label, dose-escalation trial is expected to enroll a total of 16 patients to receive the HuCNS-SC cells, administered via a single injection into the space beneath the retina in the most affected eye
The dose-escalation trial will evaluate the tablet form of the drug, with primary objectives of determining the maximum-tolerated dose and recommended Phase II dose and to assess the bioavailability and pharmacokinetics
The start of the dose-escalation study follows the FDA's approval of the investigational new drug application for Amakem, applied topically as eye drops
The trial enrolled 15 subjects, scheduled to undergo abdominoplasty, in a double-blind dose-escalation study during which single intradermal injections were administered in a dose-dependent manner to five cohorts of three subjects each
Novelos Therapeutics Inc., of Madison, Wis., said it successfully completed the second cohort in a U.S. Phase 1b dose-escalation trial of its cancer-targeted molecular radiotherapeutic compound, I-131-CLR1404 (HOT), in cancer patients with advanced solid tumors
Protalex Inc., of Summit, N.J., said data from its Phase Ib dose-escalation trial showed that PRTX-100 was well tolerated at all dose levels in adult patients with rheumatoid arthritis (RA) and, at the higher doses, more patients showed improvement in their Clinical Disease Activity Index for RA than did patients in the lower-dose or placebo cohorts
The Phase I dose-escalation portion of the trial will enroll at least six patients in each of two dose cohorts: 30 mg and 45 mg administered orally once daily
The second trial, a single-arm dose-escalation study being conducted in the U.S., will evaluate Reolysin in combination with FOLFIRI (folinic acid, fluorouracil and irinotecan) chemotherapy in 21 patients with oxaliplatin refractory, KRAS-mutant colorectal cancer
The multicenter, open-label, dose-escalation study is designed to assess safety and tolerability in patients with advanced cancer tumors, with a weighting on ovarian cancers
Protalex Inc., of Summit, N.J., said it enrolled the first patients in the fourth cohort of its Phase Ib dose-escalation trial of PRTX-100 in adults with active rheumatoid arthritis (RA) in South Africa
Primary endpoints are related to safety and reflect the dose-escalation design of the trial, which aims to find a maximum tolerated dose of different combinations of HCQ and sorafenib
The open-label, multiple-dose, dose-escalation study is enrolling about 15 patients with relapsed or refractory multiple myeloma, DLBCL and MCL, who will receive SNS01-T, a drug designed to selectively trigger apoptosis in B-cell cancers, via intravenous infusion